FUKOKU MUTUAL LIFE INSURANCE Co maintained its position in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,100 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Celgene were worth $403,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Thompson Davis & CO. Inc. raised its stake in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares in the last quarter. Motco raised its stake in shares of Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares in the last quarter. Acropolis Investment Management LLC purchased a new position in shares of Celgene during the 2nd quarter worth approximately $144,000. Rational Advisors LLC purchased a new position in shares of Celgene during the 2nd quarter worth approximately $156,000. Finally, Oakworth Capital Inc. raised its stake in shares of Celgene by 11.7% during the 2nd quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 127 shares in the last quarter. 80.17% of the stock is owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (CELG) opened at $102.56 on Wednesday. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $80,786.59, a price-to-earnings ratio of 16.03, a PEG ratio of 0.79 and a beta of 1.78.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.58 earnings per share. research analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.

Several research firms recently weighed in on CELG. Oppenheimer reaffirmed an “outperform” rating and issued a $175.00 price objective on shares of Celgene in a research note on Wednesday, August 9th. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a research note on Wednesday, August 16th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $162.00 price objective on shares of Celgene in a research note on Tuesday, September 26th. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $133.00 price objective on shares of Celgene in a research note on Monday, October 23rd. Finally, Stifel Nicolaus dropped their price objective on Celgene from $155.00 to $149.00 and set a “buy” rating for the company in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and an average price target of $139.57.

In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/06/fukoku-mutual-life-insurance-co-maintains-holdings-in-celgene-corporation-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.